Sign in or create an account to add this stock to your watchlist.
About Idera Pharmaceuticals (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IDRA
CUSIPN/A
Phone617-679-5500
Debt
Debt-to-Equity RatioN/A
Current Ratio8.89
Quick Ratio8.89
Price-To-Earnings
Trailing P/E Ratio-4.60
Forward P/E Ratio-5.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$900,000.00
Price / Sales470.84
Cash FlowN/A
Price / CashN/A
Book Value$0.46 per share
Price / Book4.24
Profitability
EPS (Most Recent Fiscal Year)($0.42)
Net Income$-65,980,000.00
Net Margins-9,117.07%
Return on Equity-82.70%
Return on Assets-73.93%
Miscellaneous
Employees62
Outstanding Shares217,310,000
Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions
What is Idera Pharmaceuticals' stock symbol?
Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."
How were Idera Pharmaceuticals' earnings last quarter?
Idera Pharmaceuticals Inc (NASDAQ:IDRA) released its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The biotechnology company earned $0.26 million during the quarter, compared to analysts' expectations of $0.17 million. Idera Pharmaceuticals had a negative return on equity of 82.70% and a negative net margin of 9,117.07%. View Idera Pharmaceuticals' Earnings History.
What price target have analysts set for IDRA?
2 brokerages have issued 12 month target prices for Idera Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Idera Pharmaceuticals' stock price to reach $4.00 in the next year. View Analyst Ratings for Idera Pharmaceuticals.
Who are some of Idera Pharmaceuticals' key competitors?
Some companies that are related to Idera Pharmaceuticals include Acceleron Pharma (XLRN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Iovance Biotherapeutics (IOVA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA) and Solid Biosciences (SLDB).
Who are Idera Pharmaceuticals' key executives?
Idera Pharmaceuticals' management team includes the folowing people:
- Mr. Vincent J. Milano, Pres, CEO & Director (Age 54)
- Mr. Louis J. Arcudi III, Principal Accounting Officer, Sr. VP of Operations, CFO, Treasurer & Assistant Sec. (Age 57)
- Dr. Jonathan Yingling, Sr. VP & Chief Scientific Officer (Age 49)
- Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 55)
- Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 63)
Has Idera Pharmaceuticals been receiving favorable news coverage?
News articles about IDRA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a news impact score of 0.19 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Idera Pharmaceuticals' major shareholders?
Idera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.23%), Artal Group S.A. (1.27%), JPMorgan Chase & Co. (1.27%), Barclays PLC (0.21%), Wasatch Advisors Inc. (0.19%) and Schwab Charles Investment Management Inc. (0.16%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Invest Corp Pillar, Julian Baker and Maxine Gowen. View Institutional Ownership Trends for Idera Pharmaceuticals.
Which major investors are selling Idera Pharmaceuticals stock?
Which major investors are buying Idera Pharmaceuticals stock?
IDRA stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Barclays PLC, Wasatch Advisors Inc., Kassirer Asset Management Corp, Bluefin Trading LLC, Schwab Charles Investment Management Inc. and New York State Common Retirement Fund. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Julian Baker and Maxine Gowen. View Insider Buying and Selling for Idera Pharmaceuticals.
How do I buy shares of Idera Pharmaceuticals?
Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Idera Pharmaceuticals' stock price today?
One share of IDRA stock can currently be purchased for approximately $1.96.
How big of a company is Idera Pharmaceuticals?
Idera Pharmaceuticals has a market capitalization of $402.02 million and generates $900,000.00 in revenue each year. The biotechnology company earns $-65,980,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.
How can I contact Idera Pharmaceuticals?
Idera Pharmaceuticals' mailing address is 167 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-679-5500 or via email at [email protected]
MarketBeat Community Rating for Idera Pharmaceuticals (IDRA)
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Idera Pharmaceuticals (NASDAQ:IDRA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Idera Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 105.13%. The high price target for IDRA is $4.00 and the low price target for IDRA is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.3333 | $5.40 | $5.40 |
| Price Target Upside: | 105.13% upside | 114.52% upside | 148.85% upside | 172.73% upside |
Idera Pharmaceuticals (NASDAQ:IDRA) Consensus Price Target History
Idera Pharmaceuticals (NASDAQ:IDRA) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Idera Pharmaceuticals (NASDAQ:IDRA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.42%
Institutional Ownership Percentage: 42.47%
Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/17/2018 | Invest Corp Pillar | Major Shareholder | Sell | 200,000 | $2.40 | $480,000.00 | |  |
| 12/15/2017 | Invest Corp Pillar | Major Shareholder | Sell | 2,300,000 | $1.96 | $4,508,000.00 | | |
| 12/13/2017 | Invest Corp Pillar | Major Shareholder | Sell | 1,100,000 | $1.93 | $2,123,000.00 | | |
| 10/26/2017 | Bros. Advisors Lp Baker | Director | Buy | 8,000,000 | $1.50 | $12,000,000.00 | | |
| 5/1/2017 | Invest Corp Pillar | Director | Sell | 450,815 | $2.26 | $1,018,841.90 | | |
| 4/25/2017 | Invest Corp Pillar | Director | Sell | 1,328,422 | $2.29 | $3,042,086.38 | | |
| 4/24/2017 | Invest Corp Pillar | Director | Sell | 437,829 | $2.29 | $1,002,628.41 | | |
| 10/7/2016 | Julian Baker | Director | Buy | 3,250,000 | $2.00 | $6,500,000.00 | | |
| 10/3/2016 | Maxine Gowen | Director | Buy | 4,102 | $2.56 | $10,501.12 | 10,543 | |
| 5/13/2016 | James A Geraghty | Director | Buy | 10,000 | $1.34 | $13,400.00 | 425,649 | |
| 5/12/2016 | Mark J Casey | VP | Buy | 34,450 | $1.44 | $49,608.00 | 34,450 | |
| 3/15/2016 | Vincent Milano | CEO | Buy | 40,000 | $1.97 | $78,800.00 | 246,527 | |
| 2/13/2015 | Julian Baker | Director | Buy | 5,333,333 | $3.75 | $19,999,998.75 | | |
| 12/16/2014 | Youssef El Zein | Director | Sell | 100,000 | $3.68 | $368,000.00 | | |
| 12/12/2014 | Vincent Milano | CEO | Buy | 200,000 | $4.00 | $800,000.00 | | |
| 5/27/2014 | James A Geraghty | Director | Buy | 10,000 | $2.65 | $26,500.00 | | |
| 12/6/2013 | James A Geraghty | Director | Buy | 40,000 | $2.72 | $108,800.00 | | |
| 9/16/2013 | James A Geraghty | Director | Buy | 60,000 | $1.90 | $114,000.00 | | |
| 8/19/2013 | James A Geraghty | Director | Buy | 300,000 | $1.75 | $525,000.00 | | |
| 5/7/2013 | C Keith Hartley | Director | Buy | 90,000 | $0.49 | $44,100.00 | | |
(Data available from 1/1/2013 forward)
Idera Pharmaceuticals (NASDAQ IDRA) News Headlines
| Source: |
|
Idera Pharmaceuticals (NASDAQ:IDRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Idera Pharmaceuticals (NASDAQ:IDRA) Income Statement, Balance Sheet and Cash Flow Statement
Idera Pharmaceuticals (NASDAQ IDRA) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
